The International Society for Cell & Gene Therapy or ISCT is a great organization in our field. They have launched a new guide to help healthcare providers navigate this complex area. Click on the image below to check it out. This new resource is important because healthcare providers, researchers, and the public need authoritative information. […]
ISCT launches new resource on unproven cell & gene therapies Read More »
People often ask me what are the most promising stem cell therapies in development and new data suggest we should add stem cells for epilepsy to the list based on work by Neurona Therapeutics. I’ll start off the weekly recommended reads with this new mouse paper on cell therapy for epilepsy. Neurona Therapeutics: stem cells
An important appeals case is pending not just for the defendants Cell Surgical Network, et al., but also for the FDA. It could impact the stem cell field very broadly too. Cell Surgical Network lawsuit status Hopefully, we’ll get a decision before the end of this year. Cell Surgical Network is a large chain of
Goldwater Institute weighs in against FDA on Cell Surgical Network lawsuit appeal Read More »
How much does stem cell therapy cost in 2024? How have prices changed? To authoritatively answer these questions now we need data from the present and past along with expert perspectives. Some surprises come up in this new analysis. In this article Intro | Stem Cell Therapy Cost: $10,000-$20,000 | Why do stem cells cost so much?
Stem cell therapy cost in 2024: data & analysis Read More »
There seems to be a never-ending supply of stem cell for hair loss research but a new article invokes a novel mechanism. Stem cell for hair loss research and cell mechanics Here’s a recent news item about a PNAS paper: Coaxing hair growth in aging hair follicle stem cells, NW Now. A common theme is things
Weekly reads: stem cell for hair loss, clinic lawsuit update, 2 big retractions Read More »
I’ve been writing The Niche now for more than 13 years and the idea of stem cells for ALS has been around that whole time. Unfortunately, it has been slow going on this front, but there are still reasons for hope. Probably now much more than ever before. I’ll start with news on one path
Weekly reads: stem cells for ALS, cell wrinkles, editors quit Read More »
With the pandemic still here but less severe there are more in-person conference opportunities including stem cell meetings. It seems certain that moving forward though that there will be far more virtual opportunities too. That’s a good thing. You can see last year’s stem cell & regenerative medicine meetings 2022 page too. 2023 stem cell
Hub of regenerative medicine & stem cell meetings 2023 Read More »
I wrote recently about how political pressure on FDA Commissioner Stephen Hahn in 2020 may have helped the Texas firm Direct Biologics move their product ExoFlo forward inside the agency. Today I analyze the ExoFlo Phase I clinical trial paper used in that push on Hahn to get the firm the IND for a Phase II
Review of ExoFlo paper used to push Direct Biologics IND inside FDA finds red flags Read More »
How promising is the idea of stem cells for MS? I have been working slowly as time permits on a piece more specifically about hematopoietic stem cell transplantation (HSCT) for MS. Two new pieces caught my eye on this topic so I’ll start with those. Stem cells for MS NurOwn Found Safe, Shows Promise in
Weekly reads: stem cells for MS, blood origins, iPSCs Read More »
An FDA FOIA dump of text messages of former Commissioner Stephen Hahn suggests that a Texas regenerative firm called Direct Biologics benefited from political pressure on him in mid-2020. Then he was asked again to help in early 2021. This was shortly before he resigned at the start of the Biden Administration. The push came from
FDA leader Stephen Hahn was pressured to aid Texas firm Direct Biologics Read More »